Akebia Ther Asset Resilience Ratio
Akebia Ther asset resilience ratio. Akebia Ther (AKBA) has an Asset Resilience Ratio of 38.11% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Akebia Ther defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Akebia Ther (2013–2021)
Asset resilience ratio of Akebia Ther from 2013 to 2021. This chart shows how Akebia Ther's Asset Resilience Ratio has changed over time. Read total liabilities of Akebia Ther for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Akebia Ther's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Akebia Ther.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $83.92 Million | 38.11% |
| Total Liquid Assets | $83.92 Million | 38.11% |
Asset Resilience Insights
- Very High Liquidity: Akebia Ther maintains exceptional liquid asset reserves at 38.11% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Akebia Ther Industry Peers by Asset Resilience Ratio
Compare Akebia Ther's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Akebia Ther Asset Resilience Ratio by Year (2013–2021)
Akebia Ther asset resilience ratio by year from 2013 to 2021. The table below shows the annual Asset Resilience Ratio data for Akebia Ther.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 0.00% | $0.00 | $529.35 Million | -- |
| 2020-12-31 | 6.21% | $39.99 Million | $644.14 Million | +6.18pp |
| 2019-12-31 | 0.03% | $245.00K | $771.20 Million | -21.74pp |
| 2018-12-31 | 21.77% | $217.00 Million | $996.54 Million | -46.21pp |
| 2017-12-31 | 67.99% | $247.64 Million | $364.25 Million | +43.67pp |
| 2016-12-31 | 24.32% | $73.01 Million | $300.22 Million | -37.72pp |
| 2015-12-31 | 62.04% | $88.68 Million | $142.94 Million | -6.56pp |
| 2014-12-31 | 68.60% | $76.14 Million | $111.00 Million | +35.88pp |
| 2013-12-31 | 32.72% | $11.34 Million | $34.66 Million | -- |
About Akebia Ther
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and … Read more